Clinical Trials Logo

Clinical Trial Summary

This will be a study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.


Clinical Trial Description

This is a multicenter, Phase 2 study to estimate SPI-62's effect on clinical features of hypercortisolism related to a benign adrenal tumor, including diabetes/impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia. Each subject who provides consent and meets all inclusion and exclusion criteria will participate in a screening period and an open-ended treatment period. Visits occur at screening/baseline, months 1, 3, 6, 9, and 12, and then quarter-annually. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05436639
Study type Interventional
Source Sparrow Pharmaceuticals
Contact Frank Czerwiec, MD
Phone +1-617-465-0328
Email fczerwiec@sparrowpharma.com
Status Recruiting
Phase Phase 2
Start date July 1, 2023
Completion date December 1, 2025